Does Aprepitant (Emend ®) influence fentanyl PK?

Effects of aprepitant (Emend ®) on the pharmacokinetics of fentanyl (Durogesic ®)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON21924

Enrollment

Registered

2013-11-27

Start date

2013-12-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

All patients using a stable dose of a fentanyl (Durogesic ®) patch (for at least 8 days, to guarantee steady state).

Interventions

- taking 3 days of aprepitant - 2x pharmacokinetic sampling

Eligibility

Inclusion criteria

Inclusion criteria: - age >= 18 years; - stable use and dose of fentanyl patch (Durogesic ®) for at least 2 weeks irrespective of the dose used; - written informed consent.

Exclusion criteria

Exclusion criteria: - Using fentanyl as rescue medication (other opioids are allowed) - serious psychiatric illness, confusion of intellectual disability - The use of strong cytochrome P450 inhibitors or inducers (as identified in the Flockhart table; appendix C).

Design outcomes

Primary

Measure	Time frame
Fentanyl pharmacokinetics (i.e.clearance).	—

Secondary

Measure	Time frame
- side effects according the CTC toxicity criteria - differences in pain intensity according the NRS	—

Contacts

Public ContactW.H. Oldenmenger

Erasmus Medical Center, Daniel den Hoed Cancer Center, P.O. Box 5201

w.h.oldenmenger@erasmusmc.nl+31 (0)10 4391439

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)